Krazati

Adagrasib, the active ingredient in Krazati, is a KRAS G12C inhibitor presented as a oral tablet for oral use. It treats KRAS G12C mutated non‑small cell lung cancer and KRAS G12C mutated colorectal cancer in adult patients.

GNH USA supplies Krazati as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Krazati targets cancers driven by the KRAS G12C mutation and is indicated for the following conditions:

- KRAS G12C mutated non‑small cell lung cancer: improves disease control and progression‑free survival in eligible patients. - KRAS G12C mutated colorectal cancer: offers therapeutic benefit after standard therapies have failed. - KRAS G12C mutated solid tumours (investigational): being evaluated in clinical studies for potential efficacy.

Adagrasib may cause a range of adverse reactions, most of which are manageable with monitoring and supportive care.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Fatigue: reduced energy levels. - Decreased appetite: reduced food intake. - Vomiting: occasional episodes. - Constipation: infrequent bowel movements.

Serious or Rare Side Effects: - Elevated liver enzymes: potential hepatotoxicity requiring monitoring. - Interstitial lung disease: respiratory symptoms indicating lung inflammation. - Cardiac toxicity: arrhythmias or QT prolongation. - Severe hypertension: marked increase in blood pressure. - Neutropenia: low neutrophil count increasing infection risk. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor liver function: baseline and periodic LFTs are recommended. - Assess cardiac status: watch for QT prolongation and arrhythmias. - Evaluate for interstitial lung disease: monitor respiratory symptoms closely. - Check for drug interactions: avoid concomitant strong CYP3A4 inhibitors. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Adagrasib can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Adagrasib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Antacids containing aluminum or magnesium: can affect absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise plasma concentrations. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Statins metabolized by CYP3A4 (e.g., simvastatin): observe for increased statin exposure and muscle toxicity.